Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Alnylam shares plunge after it stops development of resuviran

Thursday, October 6, 2016 7:30
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) practically halved on Thursday as the company ended devlopment of its resuviran drug candidate.

Revusiran, an investigational ribonucleic acid interference (RNAi) therapeutic, was being developed for the treatment of hereditary ATTR amyloidosis, a rare disease caused by the build-up of a destructive substance called amyloid within the body’s tissues.

Alnylam took the decision after a phase 2 open-label extension study revealed some disconcerting results, with patients who were taking resuviran tending to ie sooner than those on the placebo.

“Patient safety comes first,” said John Maraganore, PhD, chief executive officer at Alnylam.

“We have stopped all dosing and are actively monitoring patients across revusiran studies to ensure their safety. We will also continue to evaluate ENDEAVOUR [phase study] data to understand the potential cause of these findings,” Maraganore said.

“While this outcome is disappointing given the lack of available treatment options for patients suffering from this devastating disease, we remain committed to serving the needs of the ATTR amyloidosis community,” Maraganore said.

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.